$Exelixis (EXEL.US)$Revenue has continued to grow over the p...
$Exelixis(EXEL.US$Revenue has continued to grow over the past 5 years, with an average growth rate of 19% in the past 3 years. Operating profit declined significantly in 2019 and 2020. In 2021, it did not return to the 2018 high of 440 million, reaching only 290 million. This is due to the sharp rise in R&D expenses in the past 3 years, and net profit is similar, reaching 230 million in 2021.
In the first three quarters of 2022, revenue increased by 21%, operating profit increased 47%, and net profit increased by 56%. The increase did not stop.
The income statement shows that the company has no interest expenses, only interest income, which indicates that the cash flow is very good, and the amount of non-operating income is also very small.
The balance ratio fell from 57% to 15.5% in the past 5 years, and increased slightly to 16% in Q3 2022. Current assets reached 1.84 billion dollars, total liabilities were only 470 million, and there were no interest-bearing liabilities.
Over the past five years, the overall net cash flow operating amount was far higher than the net investment amount, resulting in many shareholder surpluses.
Currently, the price-earnings ratio is 22.8, and the price-earnings ratio is TTM 17.3, you can choose (⭐️⭐️)
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
QianmengYu : The company's products are very good, and the pipeline is full and interesting, and it may become the next major pharmaceutical manufacturer. The only problem is that when senior officials are rich, they start to get money, and equity incentives are very aggressive. Financial reports will definitely not roll over. The CFO basically guarantees that EPS meets expectations, and then more will issue equity incentives
. As a result, stocks will not rise. Of course, when it's cheap, it's also a good idea to eat in a low position and wait for Wang Shi.